Principal Financial Group Inc. Buys 9,590 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Principal Financial Group Inc. increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 306,322 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,590 shares during the period. Principal Financial Group Inc. owned 0.55% of Supernus Pharmaceuticals worth $10,032,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Meritage Portfolio Management raised its holdings in Supernus Pharmaceuticals by 22.0% during the first quarter. Meritage Portfolio Management now owns 58,803 shares of the specialty pharmaceutical company's stock worth $1,926,000 after purchasing an additional 10,622 shares in the last quarter. Robeco Institutional Asset Management B.V. purchased a new position in Supernus Pharmaceuticals in the first quarter valued at about $267,000. QRG Capital Management Inc. increased its holdings in Supernus Pharmaceuticals by 5.5% in the first quarter. QRG Capital Management Inc. now owns 17,583 shares of the specialty pharmaceutical company's stock valued at $576,000 after buying an additional 913 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 12.5% in the first quarter. Exchange Traded Concepts LLC now owns 24,881 shares of the specialty pharmaceutical company's stock valued at $815,000 after buying an additional 2,762 shares in the last quarter. Finally, Azzad Asset Management Inc. ADV purchased a new position in Supernus Pharmaceuticals in the first quarter valued at about $552,000.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday.

Supernus Pharmaceuticals Stock Down 1.3%

NASDAQ SUPN traded down $0.45 on Tuesday, hitting $33.51. The stock had a trading volume of 676,462 shares, compared to its average volume of 488,779. The company's 50-day moving average is $32.26 and its two-hundred day moving average is $33.73. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 30.19 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a one year low of $27.05 and a one year high of $40.28.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.